The current status of checkpoint inhibitors in metastatic bladder cancer

The current status of checkpoint inhibitors in metastatic bladder cancer

For many decades, no significant improvements could be achieved to prolong the survival in metastatic bladder cancer. Recently, systemic immunotherapy with checkpoint inhibitors (anti-PD-L1/anti-CTLA-4) has been introduced as a novel treatment modality for patients with metastatic bladder cancer. We...

Full description

Bibliographic Details
Main Authors: Fahmy Ahmed, Omar Ahmed, Mohd. Ghani @ Mamat, Khairul Asri, Stenzl, Arnulf, Gakis, Georgios
Format: Article
Language:English
Published: Springer Verlag 2016
Online Access:http://psasir.upm.edu.my/id/eprint/52960/
http://psasir.upm.edu.my/id/eprint/52960/1/The%20current%20status%20of%20checkpoint%20inhibitors%20in%20metastatic%20bladder%20cancer.pdf

Similar Items

Similar Items